Proteasome inhibitors and modulators of heat shock protein function

Update on Cancer Therapeutics

Volumn 1, Issue 2, 2006, Pages 91-116

  Kuhn, Deborah J ^a   Zeger, Erik L ^b   Orlowski, Robert Z ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; HSP90 inhibitors; Multiple myeloma; Non Hodgkin's lymphoma; p38 inhibitors; Ubiquitin proteasome pathway

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALKYLATING AGENT; ALPHA',BETA' EPOXYKETONE; ANTHRACYCLINE DERIVATIVE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CALPAIN; CAMPTOTHECIN; CASPASE INHIBITOR; CHYMOTRYPSIN; EPIGALLOCATECHIN GALLATE; EPOXOMICIN; GREEN TEA EXTRACT; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; KETONE DERIVATIVE; KNK 437; LACTACYSTIN; LACTACYSTIN BETA LACTONE; LEUPEPTIN; MG 115; NPI 0052; PLATINUM DERIVATIVE; POLYPHENOL DERIVATIVE; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SCIO 469; TAXANE DERIVATIVE; TRIPEPTIDE DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; VORINOSTAT;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BACKACHE; BINDING AFFINITY; BLOOD TOXICITY; BONE PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEVER; FLUID RETENTION; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MENINGITIS; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PRURITUS; RASH; REVIEW; RIGOR; SENSORY NEUROPATHY; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; STRESS; SYNCOPE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEAKNESS;

EID: 33746542134     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.05.008     Document Type: Review

References (243)

1. Lowe J., Stock D., Jap B., Zwickl P., Baumeister W., and Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science 268 (1995) 533-539
2. Groll M., Ditzel L., Lowe J., et al. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 386 (1997) 463-471
3. Unno M., Mizushima T., Morimoto Y., et al. The structure of the mammalian 20S proteasome at 2.75 Å resolution. Structure (Camb) 10 (2002) 609-618
4. Rivett A.J. The multicatalytic proteinase. Multiple proteolytic activities. J Biol Chem 264 (1989) 12215-12219
5. Chen P., and Hochstrasser M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 86 (1996) 961-972
6. Kisselev A.F., Akopian T.N., Castillo V., and Goldberg A.L. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell 4 (1999) 395-402
7. Orlowski M., Cardozo C., and Michaud C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 32 (1993) 1563-1572
8. Pickart C.M., and VanDemark A.P. Opening doors into the proteasome. Nat Struct Biol 7 (2000) 999-1001
9. Groll M., Bajorek M., Kohler A., et al. A gated channel into the proteasome core particle. Nat Struct Biol 7 (2000) 1062-1067
10. Teoh C.Y., and Davies K.J. Potential roles of protein oxidation and the immunoproteasome in MHC class I antigen presentation: the 'PrOxI' hypothesis. Arch Biochem Biophys 423 (2004) 88-96
11. Fruh K., Gossen M., Wang K., Bujard H., Peterson P.A., and Yang Y. Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex. EMBO J 13 (1994) 3236-3244
12. Rivett A.J., and Hearn A.R. Proteasome function in antigen presentation: immunoproteasome complexes, peptide production, and interactions with viral proteins. Curr Protein Pept Sci 5 (2004) 153-161
13. Ciechanover A., and Schwartz A.L. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 95 (1998) 2727-2730
14. Rajkumar S.V., Richardson P.G., Hideshima T., and Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23 (2005) 630-639
15. Voges D., Zwickl P., and Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68 (1999) 1015-1068
16. Kloetzel P.M. The proteasome and MHC class I antigen processing. Biochim Biophys Acta 1695 (2004) 225-233
17. Delhalle S., Blasius R., Dicato M., and Diederich M. A beginner's guide to NF-kappaB signaling pathways. Ann NY Acad Sci 1030 (2004) 1-13
18. Karin M., and Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signaling. Semin Immunol 12 (2000) 85-98
19. Sreedhar A.S., and Csermely P. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy, a comprehensive review. Pharmacol Ther 101 (2004) 227-257
20. Barral J.M., Broadley S.A., Schaffar G., and Hartl F.U. Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol 15 (2004) 17-29
21. Young J.C., Barral J.M., and Ulrich Hartl F. More than folding: localized functions of cytosolic chaperones. Trends Biochem Sci 28 (2003) 541-547
22. Tang D., Khaleque M.A., Jones E.L., et al. Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones 10 (2005) 46-58
23. Baker H., Patel V., Molinolo A.A., et al. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral Oncol 41 (2005) 183-199
24. Morino M., Tsuzuki T., Ishikawa Y., et al. Specific expression of HSP-27 in human tumor cell lines in vitro. In Vivo 11 (1997) 179-184
25. Lichtenfels R., Seliger B., and Atkins D. Heat shock proteins in renal cell carcinomas. Contrib Nephrol 148 (2005) 35-56
26. Storm F.K., Gilchrist K.W., Warner T.F., and Mahvi D.M. Distribution of HSP-27 and HER-2/neu in in situ and invasive ductal breast carcinomas. Ann Surg Oncol 2 (1995) 43-48
27. Ralhan R., and Kaur J. Differential expression of Mr 70,000 heat shock protein in normal, premalignant, and malignant human uterine cervix. Clin Cancer Res 1 (1995) 1217-1222
28. Huot J., Houle F., Marceau F., and Landry J. Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res 80 (1997) 383-392
29. Klein S.D., and Brune B. Heat-shock protein 70 attenuates nitric oxide-induced apoptosis in RAW macrophages by preventing cytochrome c release. Biochem J 362 (2002) 635-641
30. Li C.Y., Lee J.S., Ko Y.G., Kim J.I., and Seo J.S. Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation. J Biol Chem 275 (2000) 25665-25671
31. Lin L.Y., Lin C.Y., Ho F.M., and Liau C.S. Up-regulation of the association between heat shock protein 90 and endothelial nitric oxide synthase prevents high glucose-induced apoptosis in human endothelial cells. J Cell Biochem 94 (2005) 194-201
32. Hansen R.K., Parra I., Lemieux P., Oesterreich S., Hilsenbeck S.G., and Fuqua S.A. HSP-27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 56 (1999) 187-196
33. Oesterreich S., Weng C.N., Qiu M., Hilsenbeck S.G., Osborne C.K., and Fuqua S.A. The small heat shock protein HSP-27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 53 (1993) 4443-4448
34. Kaur J., Das S.N., Srivastava A., and Ralhan R. Cell surface expression of 70 kDa heat shock protein in human oral dysplasia and squamous cell carcinoma: correlation with clinicopathological features. Oral Oncol 34 (1998) 93-98
35. Nanbu K., Konishi I., Mandai M., et al. Prognostic significance of heat shock proteins HSP-70 and HSP-90 in endometrial carcinomas. Cancer Detect Prev 22 (1998) 549-555
36. Freeman B.C., and Yamamoto K.R. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 296 (2002) 2232-2235
37. Zhou P., Fernandes N., Dodge I.L., et al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 278 (2003) 13829-13837
38. Demand J., Alberti S., Patterson C., and Hohfeld J. Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr Biol 11 (2001) 1569-1577
39. Meacham G.C., Patterson C., Zhang W., Younger J.M., and Cyr D.M. The HSC-70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol 3 (2001) 100-105
40. Ballinger C.A., Connell P., Wu Y., et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 19 (1999) 4535-4545
41. Hohfeld J., and Jentsch S. GRP-E-like regulation of the HSC-70 chaperone by the anti-apoptotic protein BAG-1. EMBO J 16 (1997) 6209-6216
42. Sondermann H., Scheufler C., Schneider C., Hohfeld J., Hartl F.U., and Moarefi I. Structure of a Bag/HSC-70 complex: convergent functional evolution of HSP-70 nucleotide exchange factors. Science 291 (2001) 1553-1557
43. Luders J., Demand J., and Hohfeld J. The ubiquitin-related BAG-1 provides a link between the molecular chaperones HSC-70/HSP-70 and the proteasome. J Biol Chem 275 (2000) 4613-4617
44. Eustace B.K., Sakurai T., Stewart J.K., et al. Functional proteomic screens reveal an essential extracellular role for HSP-90 alpha in cancer cell invasiveness. Nat Cell Biol 6 (2004) 507-514
45. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., and Neckers L.M. Inhibition of heat shock protein HSP-90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91 (1994) 8324-8328
46. Blagosklonny M.V., Toretsky J., Bohen S., and Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP-90. Proc Natl Acad Sci USA 93 (1996) 8379-8383
47. Vinitsky A., Michaud C., Powers J.C., and Orlowski M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 31 (1992) 9421-9428
48. Fenteany G., Standaert R.F., Lane W.S., Choi S., Corey E.J., and Schreiber S.L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268 (1995) 726-731
49. Omura S., Fujimoto T., Otoguro K., et al. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J Antibiot (Tokyo) 44 (1991) 113-116
50. Imajoh-Ohmi S., Kawaguchi T., Sugiyama S., Tanaka K., Omura S., and Kikuchi H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 217 (1995) 1070-1077
51. Dick L.R., Cruikshank A.A., Destree A.T., et al. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 272 (1997) 182-188
52. Shinohara K., Tomioka M., Nakano H., Tone S., Ito H., and Kawashima S. Apoptosis induction resulting from proteasome inhibition. Biochem J 317 Pt 2 (1996) 385-388
53. Orlowski R.Z., Eswara J.R., Lafond-Walker A., Grever M.R., Orlowski M., and Dang C.V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58 (1998) 4342-4348
54. Teicher B.A., Ara G., Herbst R., Palombella V.J., and Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5 (1999) 2638-2645
55. LeBlanc R., Catley L.P., Hideshima T., et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62 (2002) 4996-5000
56. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective anti-tumor agents. Cancer Res 59 (1999) 2615-2622
57. Kuhn D., Lam W.H., Kazi A., et al. Synthetic peracetate tea polyphenols as potent proteasome inhibitors and apoptosis inducers in human cancer cells. Front Biosci 10 (2005) 1010-1023
58. Yang C.S., and Wang Z.Y. Tea and cancer. J Natl Cancer Inst 85 (1993) 1038-1049
59. Katiyar S.K., Ahmad N., and Mukhtar H. Green tea and skin. Arch Dermatol 136 (2000) 989-994
60. Park A.M., and Dong Z. Signal transduction pathways: targets for green and black tea polyphenols. J Biochem Mol Biol 36 (2003) 66-77
61. Nam S., Smith D.M., and Dou Q.P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276 (2001) 13322-13330
62. Zhu Q.Y., Zhang A., Tsang D., Huang Y., and Chen Z.Y. Stability of green tea catechins. J Agric Food Chem 45 (1997) 4624-4628
63. Lam W.H., Kazi A., Kuhn D.J., et al. A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (-)-epigallocatechin gallate [(-)-EGCG]. Bioorg Med Chem 12 (2004) 5587-5593
64. Braun H.A., Umbreen S., Groll M., et al. Tripeptide mimetics inhibit the 20S proteasome by covalent bonding to the active site threonines. J Biol Chem 280 (2005) 28394-28401
65. Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., and Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed Engl 42 (2003) 355-357
66. Macherla V.R., Mitchell S.S., Manam R.R., et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 48 (2005) 3684-3687
67. Chauhan D., Catley L., Li G., et al. Preclinical evaluation of a novel and orally active proteasome inhibitor as a therapy in relapsed/refractory multiple myeloma. J Clin Oncol 23 (2005) 222s [Abstract 3122]
68. Hanada M., Sugawara K., Kaneta K., et al. Epoxomicin, a new anti-tumor agent of microbial origin. J Antibiot (Tokyo) 45 (1992) 1746-1752
69. Spaltenstein A., Leban J.J., Huang J.J., et al. Design and synthesis of novel protease inhibitors. Tripeptide [alpha]′,[beta]′-epoxyketones as nanomolar inactivators of the proteasome. Tetrahedron Lett 37 (1996) 1343-1346
70. Sin N., Kim K.B., Elofsson M., et al. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 9 (1999) 2283-2288
71. Meng L., Mohan R., Kwok B.H., Elofsson M., Sin N., and Crews C.M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96 (1999) 10403-10408
72. Elofsson M., Splittgerber U., Myung J., Mohan R., and Crews C.M. Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha′,beta′-epoxyketones. Chem Biol 6 (1999) 811-822
73. Wilk S., and Orlowski M. Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex. J Neurochem 40 (1983) 842-849
74. Adams J., Behnke M., Chen S., et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8 (1998) 333-338
75. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 7 (2002) 9-16
76. Fahy B.N., Schlieman M.G., Mortenson M.M., Virudachalam S., and Bold R.J. Targeting Bcl-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 56 (2005) 46-54
77. Cusack Jr. J.C., Liu R., and Baldwin Jr. A.S. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Res 60 (2000) 2323-2330
78. Russo S.M., Tepper J.E., Baldwin Jr. A.S., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50 (2001) 183-193
79. Ma M.H., Yang H.H., Parker K., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9 (2003) 1136-1144
80. Ni H., Ergin M., Huang Q., et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 115 (2001) 279-286
81. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61 (2001) 3071-3076
82. Tsuruta F., Sunayama J., Mori Y., et al. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 23 (2004) 1889-1899
83. Dewson G., Snowden R.T., Almond J.B., Dyer M.J., and Cohen G.M. Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene 22 (2003) 2643-2654
84. Hideshima T., Mitsiades C., Akiyama M., et al. Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood 101 (2003) 1530-1534
85. Meriin A.B., Gabai V.L., Yaglom J., Shifrin V.I., and Sherman M.Y. Proteasome inhibitors activate stress kinases and induce HSP-72. Diverse effects on apoptosis. J Biol Chem 273 (1998) 6373-6379
86. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3 (1997) 614-620
87. Cheng E.H., Kirsch D.G., Clem R.J., et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278 (1997) 1966-1968
88. 2-M phase arrest and apoptosis. Mol Cancer Ther 1 (2002) 841-849
89. L is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem 275 (2000) 29980-29985
90. Fang G., Chang B.S., Kim C.N., Perkins C., Thompson C.B., and Bhalla K.N. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res 58 (1998) 3202-3208
91. Bentires-Alj M., Barbu V., Fillet M., et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22 (2003) 90-97
92. Loo T.W., and Clarke D.M. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J 13 (1999) 1724-1732
93. L overexpressing cells. Oncogene 22 (2003) 4953-4963
94. Scott G.K., Marden C., Xu F., Kirk L., and Benz C.C. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol Cancer Ther 1 (2002) 385-392
95. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101 (2004) 540-545
96. Fournel M., Trachy-Bourget M.C., Yan P.T., et al. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are anti-proliferative against human tumors. Cancer Res 62 (2002) 4325-4330
97. Kwon S.H., Ahn S.H., Kim Y.K., et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 277 (2002) 2073-2080
98. Zhang X.D., Gillespie S.K., Borrow J.M., and Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 3 (2004) 425-435
99. Sowa Y., Orita T., Minamikawa S., et al. Histone deacetylase inhibitor activates the Waf1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241 (1997) 142-150
100. Denlinger C.E., Rundall B.K., and Jones D.R. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 128 (2004) 740-748
101. Denlinger C.E., Keller M.D., Mayo M.W., Broad R.M., and Jones D.R. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg 127 (2004) 1078-1086
102. Pei X.Y., Dai Y., and Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10 (2004) 3839-3852
103. Boll B., Hansen H., Heuck F., et al. The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 106 (2005) 1839-1842
104. 2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res 64 (2004) 8746-8753
105. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective anti-tumor agents. Cancer Res 59 (1999) 2615-2622
106. Aghajanian C., Soignet S., Dizon D.S., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8 (2002) 2505-2511
107. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20 (2002) 4420-4427
108. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2108-2121
109. Cortes J., Thomas D., Koller C., et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10 (2004) 3371-3376
110. Blaney S.M., Bernstein M., Neville K., et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 22 (2004) 4804-4809
111. ®), in patients with advanced cancer. Clin Cancer Res 11 (2005) 3410-3416
112. Voorhees P.M., Dees E.C., O'Neil B., and Orlowski R.Z. The proteasome as a target for cancer therapy. Clin Cancer Res 9 (2003) 6316-6325
113. Yang H.H., Ma M.H., Vescio R.A., and Berenson J.R. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 21 (2003) 4239-4247
114. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101 (2003) 2377-2380
115. Thomas J.P., Arzoomanian R., Alberti D., et al. A phase I and pharmacodynamic study of the proteasome inhibitor PS-341 in combination with doxorubicin. J Clin Oncol 21 (2002) 93a [Abstract 368]
116. Dees E.C., O'Neil B., Humes E., et al. Phase I trial of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory solid tumors. J Clin Oncol 22 (2003) 217 [Abstract 868]
117. Siefker-Radtke A.O., Poulter V., Mathew P., Tu S., Logothetis C.J., and Papandreou C.N. Preliminary evidence of efficacy and tolerance for weekly intravenous bortezomib plus mitoxantrone in patients with advanced androgen-independent prostate cancer (AIPCa). J Clin Oncol 23 (2005) 394s [Abstract 4567]
118. ®) in combination with paclitaxel in advanced solid tumor patients (pts). J Clin Oncol 23 (2005) 217s [Abstract 3104]
119. Messersmith W.A., Baker S.D., Dinh K., et al. Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors. J Clin Oncol 23 (2004) 208 [Abstract 3052]
120. Albanell J., Baselga J., Guix M., et al. Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer. J Clin Oncol 22 (2003) 16 [Abstract 63]
121. Roth B.J., Dreicer R., Berg W., et al. Phase I/II trial of bortezomib (PS-341) plus docetaxel in patients with advanced androgen-independent prostate cancer. J Clin Oncol 22 (2003) 424 [Abstract 1705]
122. Aghajanian C., Dizon D., Yan X.J., et al. Phase I trial of PS-341 and carboplatin in recurrent ovarian cancer. J Clin Oncol 22 (2003) 452 [Abstract 1815]
123. Davies A.M., Lara P.N., Lau D.H., et al. The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): final results of a phase I California Cancer Consortium study. J Clin Oncol 23 (2004) 639 [Abstract 7106]
124. Voortman J., Smit E., Kuenen B., et al. A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: preliminary results of a phase IB study. J Clin Oncol 23 (2005) 160s [Abstract 2103]
125. Ryan D.P., O'Neil B., Lima C.R., et al. Phase I dose-escalation study of the proteasome inhibitor, bortezomib, plus irinotecan in patients with advanced solid tumors. J Clin Oncol 22 (2003) 228 [Abstract 915]
126. Appleman L.J., Ryan D.P., Clark J.W., et al. Phase I dose escalation study of bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors. J Clin Oncol 22 (2003) 209 [Abstract 839]
127. Iqbal S., Cole S., Yang D., et al. Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: a California Cancer Consortium study. J Clin Oncol 23 (2004) 141 [Abstract 2057]
128. Possinger K., Schippinger W., Kiewe P., et al. Phase I trial of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. J Clin Oncol 23 (2005) 66s [Abstract 755]
129. Conley B.A., Donovan E., Muir C., et al. Proteasome inhibitor bortezomib and re-irradiation (rRT) with scheduled treatment break in patients (pts) with head/neck squamous carcinoma (HNSCC). J Clin Oncol 23 (2005) 522s [Abstract 5592]
130. Berenson J., Yang H., Swift R., et al. Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I/II study. Blood 104 (2004) 64a [Abstract 209]
131. Mateos M.V., Blade J., Diaz Mediavilla J., et al. A phase I/II national, multi-center, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma patients. Blood 104 (2004) 943a [Abstract 3462]
132. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99 (2002) 4525-4530
133. ® plus thalidomide (V + T) in advanced and refractory multiple myeloma. Blood 104 (2004) 413a [Abstract 1480]
134. ®, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma. Blood 104 (2004) 64a [Abstract 210]
135. Small G.W., Somasundaram S., Moore D.T., Shi Y.Y., and Orlowski R.Z. Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther 307 (2003) 861-869
136. Small G.W., Shi Y.Y., Edmund N.A., Somasundaram S., Moore D.T., and Orlowski R.Z. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66 (2004) 1478-1490
137. Orlowski R.Z., Voorhees P.M., Garcia R.A., et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105 (2005) 3058-3065
138. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
139. Oakervee H.E., Popat R., Curry N., et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129 (2005) 755-762
140. ®) + Adriamycin™ + thalidomide + dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma. Blood 104 (2004) 659a [Abstract 2399]
141. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99 (2002) 14374-14379
142. Chanan-Khan A., Alsina M., Carroll M., et al. Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM). J Clin Oncol 24 (2005) 605s [Abstract 6682]
143. Dunleavy K., Janik J., Gea-Banacloche J., et al. Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma. Blood 104 (2004) 389a [Abstract 1385]
144. ®) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia. Blood 104 (2004) 498a [Abstract 1799]
145. Koc O.N., Bahlis N.J., Liu L., et al. A phase I trial of bortezomib in combination with fludarabine in patients with lymphoproliferative neoplasms. J Clin Oncol 23 (2005) 596s [Abstract 6647]
146. Davis N.B., Taber D.A., Ansari R.H., et al. Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study. J Clin Oncol 22 (2004) 115-119
147. Kondagunta G.V., Drucker B., Schwartz L., et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22 (2004) 3720-3725
148. Shah M.H., Young D., Kindler H.L., et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10 (2004) 6111-6118
149. Markovic S.N., Geyer S.M., Dawkins F., et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103 (2005) 2584-2589
150. Maki R.G., Kraft A.S., Scheu K., et al. A multicenter phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103 (2005) 1431-1438
151. Morris M.J., Beekman K.W., Kelly W.K., et al. Phase II study of bortezomib for castrate metastatic prostate cancer (PC). J Clin Oncol 23 (2005) 411s [Abstract 4633]
152. Sridhar S.S., Stadler W., Le L., et al. Phase 2 study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] phase II consortium. J Clin Oncol 23 (2005) 422s [Abstract 4677]
153. Johl J., Chansky K., Lara P.N., Davies A.M., Bold R., and Gandara D.R. The proteasome inhibitor PS-341 (Bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (E-SCLC): a SWOG (0327) phase II trial. J Clin Oncol 23 (2005) 632s [Abstract 7047]
154. Brown J., Von Roenn J., O'Regan R., et al. A phase II study of the proteasome inhibitor PS-341 in patients with metastatic breast cancer. J Clin Oncol 23 (2004) 13 [Abstract 546]
155. Cristofanilli M., Gonzalez-Angulo A.M., Nealy K.N., et al. A phase II trial of PS-341 in metastatic breast cancer (MBC). J Clin Oncol 22 (2004) 220 [Abstract 3102]
156. Mackay H., Major P., Townsley C., et al. A phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer. J Clin Oncol 23 (2004) 222 [Abstract 3109]
157. Stevenson J., Nho C.W., Schick J., et al. Phase II clinical/pharmacodynamic trial of the proteasome inhibitor PS-341 in advanced non-small cell lung cancer. J Clin Oncol 22 (2003) 202 [Abstract 810]
158. Meluch A.A., Spigel D.S., Greco F.A., et al. Weekly docetaxel and bortezomib in the treatment of patients with advanced hormone refractory prostate cancer (HRPC): a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 23 (2005) 436s [Abstract 4735]
159. Dreicer R., Roth B., Petrylak D., et al. Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. J Clin Oncol 23 (2004) 418 [Abstract 4654]
160. Fanucchi M.P., Fossella F., Fidias P., et al. Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a phase 2 study. J Clin Oncol 23 (2005) 629s [Abstract 7034]
161. Dragovich T., Lenz H.J., Rocha Lima C.M.S., et al. Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): interim analysis results from phase (ph) 2b study. J Clin Oncol 23 (2004) 268 [Abstract 3591]
162. Hegewisch-Becker S., Sterneck M., Schubert U., et al. Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 23 (2004) 334 [Abstract 4089]
163. Kumar S.K., Therneau T.M., Gertz M.A., et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 79 (2004) 867-874
164. Fassas A.B., and Tricot G. Chromosome 13 deletion/hypodiploidy and prognosis in multiple myeloma patients. Leuk Lymphoma 45 (2004) 1083-1091
165. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127 (2004) 165-172
166. ®, Doxil in combination with low-dose thalidomide as salvage therapy for patients with relapsed or refractory multiple myeloma and Waldenström's macroglobulinemia: encouraging preliminary results. Blood 104 (2004) 665a [Abstract 2421]
167. ®) in patients with previously untreated multiple myeloma. Blood 104 (2004) 100a [Abstract 336]
168. Alexanian R., Dimopoulos M.A., Delasalle K., and Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 80 (1992) 887-890
169. Jagannath S., Durie B.G., Wolf J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129 (2005) 776-783
170. ®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study. J Clin Oncol 23 (2005) 598s [Abstract 6653]
171. Orlowski R.Z., Peterson B.L., Caligiuri M.A., Kelly M., and Larson R.A. Bortezomib and pegylated liposomal doxorubicin as initial therapy for adult patients with symptomatic multiple myeloma: CALGB study 10301. Haematologica 90 s1 (2005) 151 [Abstract 730]
172. Barlogie B., Hollmig K., Zangari M., et al. Total therapy 3 (TT 3) for newly diagnosed myeloma, incorporating Velcade into remission induction with DT PACE: early results regarding efficacy, PBSC mobilization and toxicities. Blood 104 (2004) 156a [Abstract 538]
173. Uy G.L., Fisher N.M., Devine S.M., et al. Bortezomib given in sequence with anthracycline and thalidomide-containing regimens does not adversely affect stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Blood 104 (2004) 157a [Abstract 541]
174. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23 (2005) 676-684
175. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 667-675
176. Belch A., Kouroukis C.T., Crump M., et al. Phase II trial of bortezomib in mantle cell lymphoma. Blood 104 (2004) 175a [Abstract 608]
177. Goy A., Bernstein S., Kahl B., et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study. J Clin Oncol 23 (2005) 575s [Abstract 6563]
178. ®) in patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). Blood 104 (2004) 389a [Abstract 1386]
179. ®) in a phase II study of patients with previously untreated or treated Waldenström's macroglobulinemia (WM). Blood 104 (2004) 896a [Abstract 3278]
180. Bargou R.C., Emmerich F., Krappmann D., et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100 (1997) 2961-2969
181. ®) for the treatment of relapsed classical Hodgkin's disease. Blood 104 (2004) 722a [Abstract 2638]
182. Faderl S., Rai K.R., Gribben J., et al. Phase 2 study of three doses of single agent bortezomib in patients with fludarabine-refractory B-cell CLL. Blood 104 (2004) [Abstract 4841]
183. ®, formerly PS-341) for patients with imatinib-refractory chronic myeloid leukemia (CML) in chronic (CP) or accelerated phase (AP). Blood 102 (2003) [Abstract 4971]
184. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
185. Jagannath S., Richardson P.G., Sonneveld P., et al. Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. J Clin Oncol 24 (2005) 560s [Abstract 6501]
186. Jagannath S., Barlogie B., Berenson J.R., et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 103 (2005) 1195-1200
187. Mohrbacher A., and Levine A.M. Reversal of advanced renal dysfunction on bortezomib treatment in multiple myeloma patients. J Clin Oncol 23 (2005) 612s [Abstract 6714]
188. Zangari M., Esseltine D.L., Najarian K., et al. Response to bortezomib (BOR) and bone metabolism in multiple myeloma patients. J Clin Oncol 23 (2005) 569s [Abstract 6536]
189. Rock K.L., York I.A., Saric T., and Goldberg A.L. Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 80 (2002) 1-70
190. Wong C., Morse M., and Nair S.K. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J Immunother 21 (1998) 32-40
191. El-Shami K.M., Tirosh B., Popovic D., et al. Induction of anti-tumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide. Int J Cancer 85 (2000) 236-242
192. Sun K., Welniak L.A., Panoskaltsis-Mortari A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 101 (2004) 8120-8125
193. Chauhan D., Li G., Podar K., et al. A novel orally available proteasome inhibitor NPI-0052 induces killing in multiple myeloma cells resistant to conventional and bortezomib therapies. Blood 104 (2004) 661a [Abstract 2405]
194. Takayama S., Reed J.C., and Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 22 (2003) 9041-9047
195. Kamal A., Thao L., Sensintaffar J., et al. A high-affinity conformation of HSP-90 confers tumour selectivity on HSP-90 inhibitors. Nature 425 (2003) 407-410
196. Vilenchik M., Solit D., Basso A., et al. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor HSP-90. Chem Biol 11 (2004) 787-797
197. Tauchi K., Tsutsumi Y., Hori S., Yoshimura S., Osamura R.Y., and Watanabe K. Expression of heat shock protein 70 and c-Myc protein in human breast cancer: an immunohistochemical study. Jpn J Clin Oncol 21 (1991) 256-263
198. Ciocca D.R., Clark G.M., Tandon A.K., Fuqua S.A., Welch W.J., and McGuire W.L. Heat shock protein HSP-70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 85 (1993) 570-574
199. Maehara Y., Oki E., Abe T., et al. Overexpression of the heat shock protein HSP-70 family and p53 protein and prognosis for patients with gastric cancer. Oncology 58 (2000) 144-151
200. Rau B., Gaestel M., Wust P., et al. Preoperative treatment of rectal cancer with radiation, chemotherapy and hyperthermia: analysis of treatment efficacy and heat-shock response. Radiat Res 151 (1999) 479-488
201. Santarosa M., Favaro D., Quaia M., and Galligioni E. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer 33 (1997) 873-877
202. Langdon S.P., Rabiasz G.J., Hirst G.L., et al. Expression of the heat shock protein HSP-27 in human ovarian cancer. Clin Cancer Res 1 (1995) 1603-1609
203. Cornford P.A., Dodson A.R., Parsons K.F., et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60 (2000) 7099-7105
204. Yufu Y., Nishimura J., and Nawata H. High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leuk Res 16 (1992) 597-605
205. Becker B., Multhoff G., Farkas B., et al. Induction of HSP-90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 13 (2004) 27-32
206. Yano M., Naito Z., Tanaka S., and Asano G. Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res 87 (1996) 908-915
207. Trieb K., Gerth R., Holzer G., Grohs J.G., Berger P., and Kotz R. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br J Cancer 82 (2000) 85-87
208. Wang X.P., Qiu F.R., Liu G.Z., and Chen R.F. Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma. World J Gastroenterol 11 (2005) 1056-1059
209. Conroy S.E., Sasieni P.D., Fentiman I., and Latchman D.S. Autoantibodies to the 90 kDa heat shock protein and poor survival in breast cancer patients. Eur J Cancer 34 (1998) 942-943
210. Nathan D.F., Vos M.H., and Lindquist S. In vivo functions of the Saccharomyces cerevisiae HSP-90 chaperone. Proc Natl Acad Sci USA 94 (1997) 12949-12956
211. Fortugno P., Beltrami E., Plescia J., et al. Regulation of survivin function by HSP-90. Proc Natl Acad Sci USA 100 (2003) 13791-13796
212. Zhao C., and Wang E. Heat shock protein 90 suppresses tumor necrosis factor alpha induced apoptosis by preventing the cleavage of Bid in NIH3T3 fibroblasts. Cell Signal 16 (2004) 313-321
213. Sato S., Fujita N., and Tsuruo T. Modulation of Akt kinase activity by binding to HSP-90. Proc Natl Acad Sci USA 97 (2000) 10832-10837
214. Pandey P., Saleh A., Nakazawa A., et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J 19 (2000) 4310-4322
215. Bagatell R., and Whitesell L. Altered HSP-90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 3 (2004) 1021-1030
216. Kamal A., Boehm M.F., and Burrows F.J. Therapeutic and diagnostic implications of HSP-90 activation. Trends Mol Med 10 (2004) 283-290
217. Uehara Y., Murakami Y., Mizuno S., and Kawai S. Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology 164 (1988) 294-298
218. Schulte T.W., An W.G., and Neckers L.M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 239 (1997) 655-659
219. Whitesell L., Sutphin P., An W.G., Schulte T., Blagosklonny M.V., and Neckers L. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 14 (1997) 2809-2816
220. Supko J.G., Hickman R.L., Grever M.R., and Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an anti-tumor agent. Cancer Chemother Pharmacol 36 (1995) 305-315
221. Schulte T.W., and Neckers L.M. The benzoquinone ansamycin 17-Allylamino-17-demethoxygeldanamycin binds to HSP-90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42 (1998) 273-279
222. Banerji U., O'Donnell A., Scurr M., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23 (2005) 4152-4161
223. Burger A.M., Fiebig H.H., Stinson S.F., and Sausville E.A. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15 (2004) 377-387
224. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., and Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91 (1999) 1940-1949
225. Solit D.B., Zheng F.F., Drobnjak M., et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8 (2002) 986-993
226. Bagatell R., Khan O., Paine-Murrieta G., Taylor C.W., Akinaga S., and Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 7 (2001) 2076-2084
227. Mimnaugh E.G., Xu W., Vos M., et al. Simultaneous inhibition of HSP-90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances anti-tumor activity. Mol Cancer Ther 3 (2004) 551-566
228. Bull E.E., Dote H., Brady K.J., et al. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the HSP-90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res 10 (2004) 8077-8084
229. Kaur G., Belotti D., Burger A.M., et al. Anti-angiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 10 (2004) 4813-4821
230. Lee J.C., Laydon J.T., McDonnell P.C., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372 (1994) 739-746
231. Gallagher T.F., Seibel G.L., Kassis S., et al. Regulation of stress-induced cytokine production by pyridinylimidazoles: inhibition of CSBP kinase. Bioorg Med Chem 5 (1997) 49-64
232. Parcellier A., Schmitt E., Brunet M., Hammann A., Solary E., and Garrido C. Small heat shock proteins HSP-27 and alphaB-crystallin: cytoprotective and oncogenic functions. Antioxid Redox Signal 7 (2005) 404-413
233. Sarto C., Valsecchi C., Magni F., et al. Expression of heat shock protein 27 in human renal cell carcinoma. Proteomics 4 (2004) 2252-2260
234. Schepers H., Geugien M., van der Toorn M., et al. HSP-27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun. Exp Hematol 33 (2005) 660-670
235. Concannon C.G., Gorman A.M., and Samali A. On the role of HSP-27 in regulating apoptosis. Apoptosis 8 (2003) 61-70
236. Wang H.P., Hanlon J.G., Rainbow A.J., Espiritu M., and Singh G. Up-regulation of HSP-27 plays a role in the resistance of human colon carcinoma HT29 cells to photooxidative stress. Photochem Photobiol 76 (2002) 98-104
237. de Graauw M., Tijdens I., Cramer R., Corless S., Timms J.F., and van de Water B. Heat shock protein 27 is the major differentially phosphorylated protein involved in renal epithelial cellular stress response and controls focal adhesion organization and apoptosis. J Biol Chem (2005)
238. Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., and Adams J.L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47 (2000) 185-201
239. Hideshima T., Podar K., Chauhan D., et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23 (2004) 8766-8776
240. Ramanathan R.K., Trump D.L., Eiseman J.L., et al. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of weekly 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced tumors. J Clin Oncol 22 (2004) 14s [Abstract 3031]
241. Erlichman C., Toft D., Reid J., et al. A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer. J Clin Oncol 22 (2004) 14s [Abstract 3030]
242. Solit D.B., Egorin M., Valentin G., et al. Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygeldanamycin). J Clin Oncol 22 (2004) 14s [Abstract 3032]
243. Mitsiades C., Chanan-Khan A., Alsina M., et al. Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM). J Clin Oncol 23 (2005) 16s [Abstract 3050]